Law360, New York (June 14, 2012, 10:17 PM ET) -- If the U.S. Supreme Court decides to strike down the entire health care law it could delay the debut of biosimilars onto the U.S. market for months or even years — along with their potential to cut billions of dollars from the country's total drug spending — especially if Congress devolves into partisan squabbling over re-enacting the biosimilars provisions.
If the Patient Protection and Affordable Care Act goes down in its entirety, a possibility many court observers see as unlikely but still very real, so too...
Health Care Ruling Could Mean Years Of Delay For Biosimilars
To view the full article, take a free trial now.
